Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase

Haematologica

Volumn 95, Issue 11, 2010, Pages 1960-1963

  Beer, Philip A ^a,b,c   Campbell, Peter J ^c,d   Green, Anthony R ^a,b,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Essential thrombocythemia; Lactate dehydrogenase; Myeloproliferative neoplasm; Polycythemia vera; Primary myelofibrosis

Indexed keywords

LACTATE DEHYDROGENASE;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE MARKER; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MYELOID METAPLASIA; POLYCYTHEMIA VERA; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; THROMBOCYTHEMIA;

BIOLOGICAL MARKERS; CELL PROLIFERATION; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LEUKOCYTE COUNT; MALE; PLATELET COUNT; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; THROMBOCYTOPENIA;

EID: 78149266689     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.026708     Document Type: Article

References (12)

1. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355 (23):2452-66.
2. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7(9):673-83.
3. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366(9501):1945-53.
4. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 2008;22(5):905-14.
5. Harrison CN, Bareford D, Butt N, Campbell PJ, Conneally E, Drummond M, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br Haematol. 2010;149 (3):352-75.
6. McMullin MF, Reilly JT, Campbell P, Bareford D, Green AR, Harrison CN, et al. Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol. 2007;138(6): 821-2.
7. Barosi G, Ambrosetti A, Finelli C, Grossi A, Leoni P, Liberato NL, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol. 1999;104(4): 730-7.
8. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008.
9. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;113(3):763-71.
10. Cervantes F, Alvarez-Larran A, Talarn C, Gomez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol. 2002;118(3):786-90.
11. Mertens F, Johansson B, Heim S, Kristoffersson U, Mitelman F. Karyotypic patterns in chronic myeloproliferative disorders: report on 74 cases and review of the literature. Leukemia. 1991;5(3):214-20.
12. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88(3):1013-8.